Belimumab is under clinical development by GSK and currently in Phase III for Rheumatoid Arthritis. According to GlobalData, Phase III drugs for Rheumatoid Arthritis have a 63% phase transition ...
Also known as interstitial cystitis (IC), painful bladder syndrome (PBS) describes a chronic bladder health condition. It can cause people to experience pelvic pain and difficulty peeing.
Background Over the course of 1 year, four patients in a single institution developed acute kidney injury most likely secondary to nafcillin-associated acute interstitial nephritis, indicating ...
Both strains share MHC, but vary in anti-GBM nephritis susceptibility. The role of macrophage and IFN-γ in crescent formation was investigated using adoptive transfer of macrophages with altered IFN-γ ...
Credit: Getty Images The American College of Rheumatology has released a new guideline summary for the screening, treatment, and management of lupus nephritis. The guideline authors recommend ...
As an autoimmune disease characterized by immune imbalance, T-cell ferroptosis has attracted attention for its potential in regulating immune balance in lupus nephritis. This article reviews the ...
Department of Chemistry, The University of Tokyo, Hongo, Tokyo 113-0033, Japan ...
Antiphospholipid antibodies are a novel risk factor for end stage renal disease in patients with lupus nephritis. The presence of anti-phospholipid antibodies and a high activity index on kidney ...
Treatment for interstitial cystitis, or bladder pain syndrome (IC/BPS), includes lifestyle changes such as avoiding certain foods and managing stress. A doctor may also suggest medications ...
Researchers from both Johns Hopkins Medicine and Yale University collaborated on the development and application of a diagnostic model to detect acute interstitial nephritis (AIN) in patients, which ...
[13] Furthermore, few suspected cases of nafcillin-associated interstitial nephritis have been reported over the past 25 years. [6,9] The recent clinical experience at the institution where the ...